Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 36 clinical trials
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

efficacy occurred will be based on the occurrence of bleeding, the clotting factor VIII level in blood after injection called recovery, FVIII inhibitor tests and measurement of antibodies against the PEG

  • 27 May, 2022
  • 2 locations
Gene Therapy for Haemophilia A.

The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A

bleeding tendency
antihemophilic factor
joint pain
severe haemophilia a
  • 24 Jan, 2021
  • 3 locations
Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding (HA-SAFE)

Factor VIII (FVIII) medication for the treatment of hemophilia A (bleeding disorder resulting from a lack of FVIII). It is manufactured via recombinant technology and has an extended half-live, i.e. it

  • 05 Jun, 2022
  • 4 locations
Patient Reported Outcomes Burdens and Experiences - Phase 3 (PROBE-3)

The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data.

  • 26 May, 2022
  • 1 location
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A (EmiMSK)

the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compare the effect of routine factor VIII prophylaxis with emicizumab prophylaxis.

  • 16 May, 2022
  • 1 location
A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

The main aims of the study are to assess the safety profile of Adynovate as well as how well people respond to the preventive treatment with Adynovate. This study is about reviewing and collecting data of the participants before and after the switch to Adynovate that are already available. No …

  • 25 May, 2022
  • 1 location
ADYNOVATE Drug Use-Results Survey

adverse drug reactions in the actual clinical use Factors that may affect safety and efficacy Occurrence of Factor VIII inhibitor development in patients with coagulation factor VIII

antihemophilic factor
factor viii inhibitor
coagulation factor
  • 10 Mar, 2022
  • 49 locations
A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

This study is about a factor VIII medicine called Adynovate (TAK-660) used during surgery for people with hemophilia A who have low blood levels of factor VIII. The aims of this study are

  • 17 Oct, 2021
  • 1 location
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells (IMMUNHEMAC)

Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due

Accepts healthy volunteers
  • 21 Mar, 2022
  • 2 locations
Treatment of Hemophilia A Patients With FVIII Inhibitors

This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII

antihemophilic factor
immune tolerance induction
  • 18 Jul, 2021
  • 2 locations